Biostar Pharmaceuticals Profit Margin

Biostar Pharmaceuticals (BSPM) currently reports a profit margin of 98.6% as of September 2017. That compares with -842.53% in the prior-year period — up 111.7% year over year. That is above the sector sector average of 21.59%. Use the charts on this page to explore Biostar Pharmaceuticals's profit margin history and peer comparisons.

Biostar Pharmaceuticals's profit margin increased from -842.53% to 98.6% — a 111.7% year-over-year increase (period ending September 2017). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Biostar Pharmaceuticals's profit margin of 98.6% is higher than the its sector sector average of 21.59%. That is roughly 356.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Biostar Pharmaceuticals's current 98.6% should be judged against industry norms (sector average: 21.59%) and against BSPM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 98.6%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 21.59%. From there, open related valuation or income-statement pages for Biostar Pharmaceuticals, and consider following BSPM for alerts when major investors trade the stock.